Clinical Trial

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy

Study acronym: KYRON
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy
Protocol Amendment History 1 change
notable Enrollment increased: 45 -> 55 participants 2026-08-08
Trial Details
NCT Number NCT07600736
Lead Sponsor Actio Biosciences, Inc.
Conditions KCNT1-Related Epilepsy
Enrollment 55 participants
Start Date 2026-05-18
Primary Completion 2027-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-07